URGN 12.79 (+5.53%)
IL0011407140BiotechnologyBiotechnology

UroGen Pharma (URGN) Financial Metrics

This table shows a selected set of financial data points of UroGen Pharma (URGN). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -3.55 0 -4.23 432.51M -0.65 82.71M -76.57M -60.35M -102.24M 95M
2022 -4.81 0 -1.84 202.3M -0.86 64.36M -87.81M -76.21M -109.78M 55.41M
2021 -4.96 0 -1.92 212.52M -0.92 48.04M -85.64M -90.31M -110.82M 44.36M
2020 -5.9 0 -3.05 392.49M -0.79 11.8M -107.1M -124.7M -128.48M 52.86M
2019 -5.12 0 -6.52 685.04M -0.69 18K -71.34M -108.15M -105.15M 49.69M
2018 -4.8 0 -8.97 678.38M -0.84 1.13M -37.89M -75.12M -75.66M 101.32M
2017 -2.06 0 -18.08 361.56M -0.41 8.16M -9.84M -19.77M -20M 37M
2016 -0.16 0 0 0 -0.09 17.53M 3.49M -1.73M -1.94M 21.36M
2015 -1.06 0 0 0 -1.07 0 -7.48M -12.58M -12.69M 17.98M
2014 -4.48 0 0 0 -1.18 0 0 0 -4.48M 3.87M
2013 0 0 0 0 0 0 0 0 -3.31M 3.04M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.